English

Solid Biosciences Inc.

EDGAR

SLDB Quarterly report (10-Q) · filed 2026-08-06

57 filing records in this dataset, filed from 2017-12-29 to 2026-08-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2020 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

1.31 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -56599000 USD Source
Operating Cash Flow: -57906000 USD Source

Free cash flow

1.25 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -56599000 USD Source
Operating Cash Flow: -57906000 USD Source
Capital Expenditure: 899000 USD Source
Capital Expenditure: 839000 USD Source

Cash and cash equivalents: 159 million USD 2026-06-30 Source
Exact value

159394000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 105 million shares 2026-06-30 Source
Exact value

105125366 shares

Reported share-count change

35.47% · 27.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

77602741 shares · 2025-06-30· Source
105125366 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2020-01-01 – 2020-12-31

Exact inputs and evidence

Revenue: 0 USD · 2020-01-01 – 2020-03-31 Source
Revenue: 0 USD · 2020-04-01 – 2020-06-30 Source
Revenue: 0 USD · 2020-07-01 – 2020-09-30 Source
Revenue: 0 USD · 2020-01-01 – 2020-12-31 Source
Revenue: 0 USD · 2020-01-01 – 2020-09-30 Source

Operating cash flow

-187 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -102734000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -69262000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -156300000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -102734000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -47230000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -99817000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -47230000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

965 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 588000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 503000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1153000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 588000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 165000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 315000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 165000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-188 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -102734000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -69262000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -156300000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -102734000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -47230000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -99817000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -47230000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 588000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 503000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1153000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 588000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 165000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 315000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 165000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2022-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 4 of 11 periods available· newest 2019-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 9 of 11 periods available· newest 2025-12-31
Total liabilities: 9 of 11 periods available· newest 2025-12-31
Current assets: 9 of 11 periods available· newest 2025-12-31
Current liabilities: 9 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Operating cash flow
−USD 56.29 million

Prior period

−USD 100.01 million

2024-01-01 – 2024-12-31
Current period

−USD 156.3 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-156300000 − -100012000 = -56288000 USD

-100012000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-156300000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Solid Biosciences Inc. · 2025-12-31 Solid Biosciences Inc. (edgar:1707502) Year-over-year change in Operating cash flow: -56288000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -156300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2660113 Filing: 000119312526115928 Input fundies:OperatingCashFlow: -100012000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2490582 Filing: 000119312526115928
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+76.3%

Prior period

USD 654,000

2024-01-01 – 2024-12-31
Current period

USD 1.15 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1153000 − 654000 = 499000 USD

654000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1153000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Solid Biosciences Inc. · 2025-12-31 Solid Biosciences Inc. (edgar:1707502) Year-over-year change in Capital expenditure: 499000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1153000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2495434 Filing: 000119312526115928 Input fundies:CapitalExpenditure: 654000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2497200 Filing: 000119312526115928
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 8.09 million 100% of revenue
Operating costs Derived USD 114.55 million 1,415% of revenue
Operating income −USD 106.45 million −1,315% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −USD 97.98 million −1,210% of revenue
Capital expenditure USD 3.02 million 37% of revenue
Free cash flow Derived −USD 100.99 million −1,248% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	0	25576000 Derived	-25576000	-4037000 Derived	-21539000	-20512000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -25576000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -21539000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -20120000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 392000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	0	54857000 Derived	-54857000	-2739000 Derived	-52118000	-45500000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -54857000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -52118000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -43224000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2276000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	0	75687000 Derived	-75687000	-889000 Derived	-74798000	-77973000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -75687000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -74798000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -70197000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 7776000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	0	119318000 Derived	-119318000	-2095000 Derived	-117223000	-97101000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -119318000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -117223000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -92714000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 4387000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	88406000 Derived	-88406000	Unavailable	Unavailable	-57498000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -88406000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -56599000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 899000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	13620000	85874000 Derived	-72254000	Unavailable	Unavailable	-79045000 Derived	Source 2021-01-01 – 2021-12-31: 13620000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -72254000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -77764000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1281000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	8094000	114546000 Derived	-106452000	Unavailable	Unavailable	-100992000 Derived	Source 2022-01-01 – 2022-12-31: 8094000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -106452000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -97977000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3015000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 8.1M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source
20182018-12-31	Revenue	0	Revenue: 0 Open source
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	13620000	Revenue: 13620000 Open source
20222022-12-31	Revenue	8094000	Revenue: 8094000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-40.6% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 13620000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	-40.6%	Revenue: 8094000 Open source Revenue: 13620000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,315.2% 2022

Free cash flow margin -1,247.7% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -25576000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -54857000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -75687000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -119318000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -88406000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-530.5%	Operating Income: -72254000 Open source Revenue: 13620000 Open source
20222022-12-31	Operating margin	-1,315.2%	Operating Income: -106452000 Open source Revenue: 8094000 Open source
20162016-12-31	Net margin	Not reported	Net Income: -21539000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -52118000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -74798000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -117223000 Open source Revenue: 0 Open source
2020-12-31	Net margin	Not reported	Revenue: 0 Open source
2021-12-31	Net margin	Not reported	Revenue: 13620000 Open source
2022-12-31	Net margin	Not reported	Revenue: 8094000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -20120000 Open source Capital Expenditure: 392000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -43224000 Open source Capital Expenditure: 2276000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -70197000 Open source Capital Expenditure: 7776000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -92714000 Open source Capital Expenditure: 4387000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -56599000 Open source Capital Expenditure: 899000 Open source
20212021-12-31	Free cash flow margin	-580.4%	Revenue: 13620000 Open source Operating Cash Flow: -77764000 Open source Capital Expenditure: 1281000 Open source
20222022-12-31	Free cash flow margin	-1,247.7%	Revenue: 8094000 Open source Operating Cash Flow: -97977000 Open source Capital Expenditure: 3015000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -98M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-20120000	Operating Cash Flow: -20120000 Open source
20172017-12-31	Operating cash flow	-43224000	Operating Cash Flow: -43224000 Open source
20182018-12-31	Operating cash flow	-70197000	Operating Cash Flow: -70197000 Open source
20192019-12-31	Operating cash flow	-92714000	Operating Cash Flow: -92714000 Open source
20202020-12-31	Operating cash flow	-56599000	Operating Cash Flow: -56599000 Open source
20212021-12-31	Operating cash flow	-77764000	Operating Cash Flow: -77764000 Open source
20222022-12-31	Operating cash flow	-97977000	Operating Cash Flow: -97977000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -101M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-20512000	Operating Cash Flow: -20120000 Open source Capital Expenditure: 392000 Open source
20172017-12-31	Free cash flow	-45500000	Operating Cash Flow: -43224000 Open source Capital Expenditure: 2276000 Open source
20182018-12-31	Free cash flow	-77973000	Operating Cash Flow: -70197000 Open source Capital Expenditure: 7776000 Open source
20192019-12-31	Free cash flow	-97101000	Operating Cash Flow: -92714000 Open source Capital Expenditure: 4387000 Open source
20202020-12-31	Free cash flow	-57498000	Operating Cash Flow: -56599000 Open source Capital Expenditure: 899000 Open source
20212021-12-31	Free cash flow	-79045000	Operating Cash Flow: -77764000 Open source Capital Expenditure: 1281000 Open source
20222022-12-31	Free cash flow	-100992000	Operating Cash Flow: -97977000 Open source Capital Expenditure: 3015000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

18.7% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
20172017-12-31	Liabilities / assets	14.8%	Total Liabilities: 11271000 Open source Total Assets: 76193000 Open source
20182018-12-31	Liabilities / assets	10.3%	Total Liabilities: 14414000 Open source Total Assets: 139597000 Open source
20192019-12-31	Liabilities / assets	22.6%	Total Liabilities: 23423000 Open source Total Assets: 103471000 Open source
20202020-12-31	Liabilities / assets	22.8%	Total Liabilities: 39083000 Open source Total Assets: 171169000 Open source
20212021-12-31	Liabilities / assets	10.4%	Total Liabilities: 24169000 Open source Total Assets: 232380000 Open source
20222022-12-31	Liabilities / assets	18.7%	Total Liabilities: 48586000 Open source Total Assets: 260252000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.76× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
20172017-12-31	Current assets / current liabilities	6.27×	Current Assets: 70658000 Open source Current Liabilities: 11271000 Open source
20182018-12-31	Current assets / current liabilities	10.31×	Current Assets: 128639000 Open source Current Liabilities: 12481000 Open source
20192019-12-31	Current assets / current liabilities	4.72×	Current Assets: 86302000 Open source Current Liabilities: 18276000 Open source
20202020-12-31	Current assets / current liabilities	6.49×	Current Assets: 158901000 Open source Current Liabilities: 24480000 Open source
20212021-12-31	Current assets / current liabilities	9.43×	Current Assets: 222612000 Open source Current Liabilities: 23601000 Open source
20222022-12-31	Current assets / current liabilities	9.76×	Current Assets: 219638000 Open source Current Liabilities: 22508000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 21.54 million Exact value Exact value: -21539000 USD 2016-01-01 – 2016-12-31: -21539000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Solid Biosciences Inc. · 2016-12-31 Solid Biosciences Inc. (edgar:1707502) Net Income: -21539000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21539000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459019007462/sldb-20181231.xml#148603 Filing: 000156459019007462 The citation records this snapshot. The page link may show a newer release later.	−USD 20.12 million Exact value Exact value: -20120000 USD 2016-01-01 – 2016-12-31: -20120000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2016-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -20120000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20120000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459019007462/sldb-20181231.xml#187256 Filing: 000156459019007462 The citation records this snapshot. The page link may show a newer release later.	USD 392,000 Exact value Exact value: 392000 USD 2016-01-01 – 2016-12-31: 392000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2016-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 392000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 392000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459019007462/sldb-20181231.xml#187888 Filing: 000156459019007462 The citation records this snapshot. The page link may show a newer release later.	−USD 20.51 million Calculation and evidence -20120000 − 392000 USD Exact free cash flow: -20512000 USD 2016-01-01 – 2016-12-31: -20120000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 392000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2016-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -20512000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20120000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459019007462/sldb-20181231.xml#187256 Filing: 000156459019007462 Input fundies:CapitalExpenditure: 392000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459019007462/sldb-20181231.xml#187888 Filing: 000156459019007462 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 52.12 million Exact value Exact value: -52118000 USD 2017-01-01 – 2017-12-31: -52118000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Solid Biosciences Inc. · 2017-12-31 Solid Biosciences Inc. (edgar:1707502) Net Income: -52118000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52118000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459020010247/sldb-20191231.xml#176207 Filing: 000156459020010247 The citation records this snapshot. The page link may show a newer release later.	−USD 43.22 million Exact value Exact value: -43224000 USD 2017-01-01 – 2017-12-31: -43224000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2017-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -43224000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43224000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459020010247/sldb-20191231.xml#225180 Filing: 000156459020010247 The citation records this snapshot. The page link may show a newer release later.	USD 2.28 million Exact value Exact value: 2276000 USD 2017-01-01 – 2017-12-31: 2276000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2017-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 2276000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2276000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459020010247/sldb-20191231.xml#225812 Filing: 000156459020010247 The citation records this snapshot. The page link may show a newer release later.	−USD 45.5 million Calculation and evidence -43224000 − 2276000 USD Exact free cash flow: -45500000 USD 2017-01-01 – 2017-12-31: -43224000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2276000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2017-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -45500000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43224000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459020010247/sldb-20191231.xml#225180 Filing: 000156459020010247 Input fundies:CapitalExpenditure: 2276000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459020010247/sldb-20191231.xml#225812 Filing: 000156459020010247 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 74.8 million Exact value Exact value: -74798000 USD 2018-01-01 – 2018-12-31: -74798000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Solid Biosciences Inc. · 2018-12-31 Solid Biosciences Inc. (edgar:1707502) Net Income: -74798000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74798000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459020010247/sldb-20191231.xml#176053 Filing: 000156459020010247 The citation records this snapshot. The page link may show a newer release later.	−USD 70.2 million Exact value Exact value: -70197000 USD 2018-01-01 – 2018-12-31: -70197000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2018-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -70197000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70197000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459021013153/sldb-10k_20201231.htm#3608358 Filing: 000156459021013153 The citation records this snapshot. The page link may show a newer release later.	USD 7.78 million Exact value Exact value: 7776000 USD 2018-01-01 – 2018-12-31: 7776000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2018-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 7776000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7776000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459021013153/sldb-10k_20201231.htm#3619375 Filing: 000156459021013153 The citation records this snapshot. The page link may show a newer release later.	−USD 77.97 million Calculation and evidence -70197000 − 7776000 USD Exact free cash flow: -77973000 USD 2018-01-01 – 2018-12-31: -70197000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 7776000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2018-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -77973000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70197000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459021013153/sldb-10k_20201231.htm#3608358 Filing: 000156459021013153 Input fundies:CapitalExpenditure: 7776000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459021013153/sldb-10k_20201231.htm#3619375 Filing: 000156459021013153 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 117.22 million Exact value Exact value: -117223000 USD 2019-01-01 – 2019-12-31: -117223000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Solid Biosciences Inc. · 2019-12-31 Solid Biosciences Inc. (edgar:1707502) Net Income: -117223000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -117223000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459020010247/sldb-20191231.xml#175898 Filing: 000156459020010247 The citation records this snapshot. The page link may show a newer release later.	−USD 92.71 million Exact value Exact value: -92714000 USD 2019-01-01 – 2019-12-31: -92714000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2019-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -92714000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -92714000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459022009963/sldb-10k_20211231.htm#3341887 Filing: 000156459022009963 The citation records this snapshot. The page link may show a newer release later.	USD 4.39 million Exact value Exact value: 4387000 USD 2019-01-01 – 2019-12-31: 4387000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2019-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 4387000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4387000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459022009963/sldb-10k_20211231.htm#3352888 Filing: 000156459022009963 The citation records this snapshot. The page link may show a newer release later.	−USD 97.1 million Calculation and evidence -92714000 − 4387000 USD Exact free cash flow: -97101000 USD 2019-01-01 – 2019-12-31: -92714000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 4387000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2019-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -97101000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -92714000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459022009963/sldb-10k_20211231.htm#3341887 Filing: 000156459022009963 Input fundies:CapitalExpenditure: 4387000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000156459022009963/sldb-10k_20211231.htm#3352888 Filing: 000156459022009963 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−USD 56.6 million Exact value Exact value: -56599000 USD 2020-01-01 – 2020-12-31: -56599000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2020-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -56599000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -56599000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017023009318/sldb-20221231.htm#2618415 Filing: 000095017023009318 The citation records this snapshot. The page link may show a newer release later.	USD 899,000 Exact value Exact value: 899000 USD 2020-01-01 – 2020-12-31: 899000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2020-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 899000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 899000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017023009318/sldb-20221231.htm#2629756 Filing: 000095017023009318 The citation records this snapshot. The page link may show a newer release later.	−USD 57.5 million Calculation and evidence -56599000 − 899000 USD Exact free cash flow: -57498000 USD 2020-01-01 – 2020-12-31: -56599000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 899000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2020-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -57498000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -56599000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017023009318/sldb-20221231.htm#2618415 Filing: 000095017023009318 Input fundies:CapitalExpenditure: 899000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017023009318/sldb-20221231.htm#2629756 Filing: 000095017023009318 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−USD 77.76 million Exact value Exact value: -77764000 USD 2021-01-01 – 2021-12-31: -77764000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2021-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -77764000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -77764000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2015820 Filing: 000095017024030508 The citation records this snapshot. The page link may show a newer release later.	USD 1.28 million Exact value Exact value: 1281000 USD 2021-01-01 – 2021-12-31: 1281000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2021-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 1281000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1281000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2022724 Filing: 000095017024030508 The citation records this snapshot. The page link may show a newer release later.	−USD 79.05 million Calculation and evidence -77764000 − 1281000 USD Exact free cash flow: -79045000 USD 2021-01-01 – 2021-12-31: -77764000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1281000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2021-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -79045000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -77764000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2015820 Filing: 000095017024030508 Input fundies:CapitalExpenditure: 1281000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2022724 Filing: 000095017024030508 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−USD 97.98 million Exact value Exact value: -97977000 USD 2022-01-01 – 2022-12-31: -97977000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2022-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -97977000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -97977000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2014386 Filing: 000095017024030508 The citation records this snapshot. The page link may show a newer release later.	USD 3.02 million Exact value Exact value: 3015000 USD 2022-01-01 – 2022-12-31: 3015000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2022-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 3015000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3015000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2021404 Filing: 000095017024030508 The citation records this snapshot. The page link may show a newer release later.	−USD 100.99 million Calculation and evidence -97977000 − 3015000 USD Exact free cash flow: -100992000 USD 2022-01-01 – 2022-12-31: -97977000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3015000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2022-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -100992000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -97977000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2014386 Filing: 000095017024030508 Input fundies:CapitalExpenditure: 3015000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017024030508/sldb-20231231.htm#2021404 Filing: 000095017024030508 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	Unavailable Not reported for this period.	−USD 94.18 million Exact value Exact value: -94180000 USD 2023-01-01 – 2023-12-31: -94180000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2023-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -94180000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -94180000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017025034644/sldb-20241231.htm#3064946 Filing: 000095017025034644 The citation records this snapshot. The page link may show a newer release later.	USD 1.52 million Exact value Exact value: 1515000 USD 2023-01-01 – 2023-12-31: 1515000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2023-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 1515000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1515000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017025034644/sldb-20241231.htm#3071089 Filing: 000095017025034644 The citation records this snapshot. The page link may show a newer release later.	−USD 95.7 million Calculation and evidence -94180000 − 1515000 USD Exact free cash flow: -95695000 USD 2023-01-01 – 2023-12-31: -94180000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1515000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2023-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -95695000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -94180000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017025034644/sldb-20241231.htm#3064946 Filing: 000095017025034644 Input fundies:CapitalExpenditure: 1515000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000095017025034644/sldb-20241231.htm#3071089 Filing: 000095017025034644 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	Unavailable Not reported for this period.	−USD 100.01 million Exact value Exact value: -100012000 USD 2024-01-01 – 2024-12-31: -100012000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2024-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -100012000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -100012000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2490582 Filing: 000119312526115928 The citation records this snapshot. The page link may show a newer release later.	USD 654,000 Exact value Exact value: 654000 USD 2024-01-01 – 2024-12-31: 654000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2024-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 654000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 654000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2497200 Filing: 000119312526115928 The citation records this snapshot. The page link may show a newer release later.	−USD 100.67 million Calculation and evidence -100012000 − 654000 USD Exact free cash flow: -100666000 USD 2024-01-01 – 2024-12-31: -100012000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 654000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2024-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -100666000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -100012000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2490582 Filing: 000119312526115928 Input fundies:CapitalExpenditure: 654000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2497200 Filing: 000119312526115928 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	Unavailable Not reported for this period.	−USD 156.3 million Exact value Exact value: -156300000 USD 2025-01-01 – 2025-12-31: -156300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Solid Biosciences Inc. · 2025-12-31 Solid Biosciences Inc. (edgar:1707502) Operating Cash Flow: -156300000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -156300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2660113 Filing: 000119312526115928 The citation records this snapshot. The page link may show a newer release later.	USD 1.15 million Exact value Exact value: 1153000 USD 2025-01-01 – 2025-12-31: 1153000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Solid Biosciences Inc. · 2025-12-31 Solid Biosciences Inc. (edgar:1707502) Capital Expenditure: 1153000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1153000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2495434 Filing: 000119312526115928 The citation records this snapshot. The page link may show a newer release later.	−USD 157.45 million Calculation and evidence -156300000 − 1153000 USD Exact free cash flow: -157453000 USD 2025-01-01 – 2025-12-31: -156300000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1153000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Solid Biosciences Inc. · 2025-12-31 Solid Biosciences Inc. (edgar:1707502) Free cash flow: -157453000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1707502?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -156300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2660113 Filing: 000119312526115928 Input fundies:CapitalExpenditure: 1153000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm#2495434 Filing: 000119312526115928 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

57 filings · 1,947 latest values · 1,947 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001707502, 1707502, SLDB, edgar:1707502, sldb

Also known as Solid Biosciences Inc., Solid Biosciences, LLC

Solid Biosciences Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation